Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy

Neuropediatrics

Volumn 46, Issue 6, 2015, Pages 371-376

  Wood, Claire L ^a,b   Cheetham, Tim D ^a,b   Guglieri, Michela ^a   Bushby, Kate ^a   Owen, Catherine ^b   Johnstone, Helen ^b   Straub, Volker ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

Author keywords

corticosteroids; Duchenne muscular dystrophy; growth; hypogonadism; puberty; testosterone

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; TESTOSTERONE; VITAMIN D; GLUCOCORTICOID;

ADOLESCENT; ANDROGEN THERAPY; ARTICLE; BODY GROWTH; BODY HEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DELAYED PUBERTY; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; FEEDBACK SYSTEM; FOLLOW UP; HUMAN; LOCAL SKIN REACTION; MALE; MUSCLE FUNCTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; COMPLICATION; DRUG EFFECTS; MUSCULAR DYSTROPHY, DUCHENNE; PUBERTY, DELAYED;

ADOLESCENT; BODY HEIGHT; GLUCOCORTICOIDS; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PUBERTY, DELAYED; RETROSPECTIVE STUDIES; TESTOSTERONE;

EID: 84948075506     PISSN: 0174304X     EISSN: 14391899     Source Type: Journal    
DOI: 10.1055/s-0035-1563696     Document Type: Article

References (24)

1. Emery A. E. Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord: 1991; 1 1 19 29
2. Bushby K., Finkel R., Birnkrant D. J., et al. DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol: 2010; 9 1 77 93
3. Moxley R. T. III, Pandya S., Ciafaloni E., Fox D. J., Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol: 2010; 25 9 1116 1129
4. Wagner K. R., Lechtzin N., Judge D. P. Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta: 2007; 1772 2 229 237
5. Markham L. W., Kinnett K., Wong B. L., Woodrow Benson D., Cripe L. H. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord: 2008; 18 5 365 370
6. Daftary A. S., Crisanti M., Kalra M., Wong B., Amin R. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics: 2007; 119 2 e320 e324
7. Lebel D. E., Corston J. A., McAdam L. C., Biggar W. D., Alman B. A. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg Am: 2013; 95 12 1057 1061
8. Mason A., Wong S. C., McGrogan P., Ahmed S. F. Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease. Horm Res Paediatr: 2011; 75 1 8 13
9. Landon C., Rosenfeld R. G. Short stature and pubertal delay in male adolescents with cystic fibrosis. Androgen treatment. Am J Dis Child: 1984; 138 4 388 391
10. Cole T. J., Freeman J. V., Preece M. A. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med: 1998; 17 4 407 429
11. Cole T. J. Growth monitoring with the British 1990 growth reference. Arch Dis Child: 1997; 76 1 47 49
12. Biggar W. D., Harris V. A., Eliasoph L., Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord: 2006; 16 4 249 255
13. Merlini L., Gennari M., Malaspina E., et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve: 2012; 45 6 796 802
14. Rapaport D., Colletto G. M., Vainzof M., Duaik M. C., Zatz M. Short stature in Duchenne muscular dystrophy. Growth Regul: 1991; 1 1 11 15
15. Rutter M. M., Collins J., Rose S. R., et al. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord: 2012; 22 12 1046 1056
16. Bianchi M. L., Biggar D., Bushby K., Rogol A. D., Rutter M. M., Tseng B. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord: 2011; 21 4 298 303
17. Nereo N. E., Fee R. J., Hinton V. J. Parental stress in mothers of boys with duchenne muscular dystrophy. J Pediatr Psychol: 2003; 28 7 473 484
18. Zacharin M. R., Warne G. L. Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets. Arch Dis Child: 1997; 76 6 495 499
19. Katznelson L., Finkelstein J. S., Schoenfeld D. A., Rosenthal D. I., Anderson E. J., Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab: 1996; 81 12 4358 4365
20. Brodsky I. G., Balagopal P., Nair K. S. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab: 1996; 81 10 3469 3475
21. Fenichel G. M., Griggs R. C., Kissel J., et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology: 2001; 56 8 1075 1079
22. Stanhope R., Preece M. A. Management of constitutional delay of growth and puberty. Arch Dis Child: 1988; 63 9 1104 1110
23. Henricson E. K., Abresch R. T., Cnaan A., et al. CINRG Investigators. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve: 2013; 48 1 55 67
24. Tanner J. M., Whitehouse R. H. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child: 1976; 51 3 170 179